Abstract: The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They may useful in the treatment of a number of conditions, including pain and epilepsy.

Abstract: The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4 and R5 are as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They may useful in the treatment of a number of conditions, including pain and epilepsy.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Abstract: A separator for a gas stream has a horizontal tank with a fluid inlet, a fluid outlet and a flow path along the inside of the horizontal tank. A flow barrier is disposed within the tank between the inlet and the outlet. One or more sets of liquid ports are in fluid communication with the tank and positioned at a bottom surface of the tank. Each set of liquid outlets has a first port and a second port. The first port is positioned upstream along the flow path relative to the second port. A fluid passage is in fluid communication with the first port and the second port. The fluid passage defines a secondary flow path adjacent to the horizontal tank, where the first port acts as a draft inlet to the secondary flow path and the second port acts as a draft outlet from the secondary flow path to the tank.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor.

Abstract: A separator for a wet gas stream has an upper section having an outer peripheral wall, a top, and a bottom perforated baffle. A cone-shaped baffle is positioned on the perforated bottom baffle and extending toward the inlet in the top of the upper section. A spiral baffle has a bottom edge adjacent to the cone-shaped baffle and a top edge adjacent to the top of the upper section. The spiral baffle defines a curved flow path between the inlet and the outlet of the upper portion. A vortex flow section is defined by the cone-shaped baffle and the outer peripheral wall. The vortex flow section is fed by the curved flow path defined by the cone-shaped baffle. A lower section is below the perforated baffle. The lower section has a gas outlet and a liquid outlet.

Abstract: A separator for a gas stream has a horizontal tank with a fluid inlet, a fluid outlet and a flow path along the inside of the horizontal tank. A flow barrier is disposed within the tank between the inlet and the outlet. One or more sets of liquid ports are in fluid communication with the tank and positioned at a bottom surface of the tank. Each set of liquid outlets has a first port and a second port. The first port is positioned upstream along the flow path relative to the second port. A fluid passage is in fluid communication with the first port and the second port. The fluid passage defines a secondary flow path adjacent to the horizontal tank, where the first port acts as a draft inlet to the secondary flow path and the second port acts as a draft outlet from the secondary flow path to the tank.

Abstract: There is provided a separator for a gas stream. The separator has a vertical tank having a side wail, a top and a bottom. The tank has an inlet, a gas outlet, and a liquid outlet, the liquid outlet being located at the bottom of the tank.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.

Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Abstract: An assembly may include a fitting, a first pipe, and a first seal. The fitting may include an annular body having a first insertion end and an inner diametrical surface having a first knurled portion disposed adjacent the first insertion end. The first pipe may include a first end portion that is received into the first insertion end of the body and an outer diametrical surface including knurls formed thereon. The knurls of the outer diametrical surface may engage the first knurled portion of the fitting. The first seal element may be disposed within the fitting and may sealingly engage the first pipe and the fitting body. The engagement between the inner diametrical surface of the fitting and the outer diametrical surface of the pipe may a press fit and/or an interference fit.

Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or pharmaceutically acceptable salts thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes and to methods of treatment; wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.

Abstract: The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R1, R2, R3, R4, R5 and R6 are as defined in the description.

Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Abstract: A separator for a wet gas stream has an upper section having an outer peripheral wall, a top, and a bottom perforated baffle. A cone-shaped baffle is positioned on the perforated bottom baffle and extending toward the inlet in the top of the upper section. A spiral baffle has a bottom edge adjacent to the cone-shaped baffle and a top edge adjacent to the top of the upper section. The spiral baffle defines a curved flow path between the inlet and the outlet of the upper portion. A vortex flow section is defined by the cone-shaped baffle and the outer peripheral wall. The vortex flow section is fed by the curved flow path defined by the cone-shaped baffle. A lower section is below the perforated baffle. The lower section has a gas outlet and a liquid outlet.

Abstract: A separator for a wet gas stream has an upper conduit having an inlet, an outlet and an outer peripheral wall. A helical baffle is positioned within the upper conduit defining a helical flow path. The helical flow path generates a vortex in gas flowing through the upper conduit, such that liquids in the gas stream move toward the outer peripheral wall. A lower conduit has an input in axial alignment with the outlet of the upper conduit and an outlet. The input of the lower conduit and the output of the upper conduit are separated by a gap, such that liquids are ejected from the upper conduit without entering the lower conduit, and such that the gas stream within the upper conduit is transferred to the lower conduit.

Abstract: A method of snap-shot data training to determine the optimum timing of the DQS enable signal in a single read operation is provided. This is accomplished by first writing a Gray code count sequence into the memory and then reading it back in a single burst. The controller samples the read burst at a fixed interval from the time the command was issued to determine the loop-around delay. A simple truth table lookup determines the optimum DQS enable timing for normal reads. Advantageously, during normal read operations, the first positive edge of the enabled DQS signal is used to sample a counter that is enabled every time a command is issued. If the counter sample changes, indicating timing drift has occurred, the DQS enable signal can be adjusted to compensate for the drift and maintain a position centered in the DQS preamble. This technique can also be applied to a system that uses the iterative approach to determining DQS enable timing on power up.